Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Amneal Pharmaceuticals, Inc. AMRX

Set alert

Price alert · AMRX

All alert types
20.44 USD -1.07 -4.97%

At close

20.44 0.00 0.00%

Pre-market · Nov 3, 4:00 AM ET

Bid
20.44 × 1
Ask
20.47 × 1
20.30 Day range 21.68
10.68 52-week range 21.68
YTD
+62.22%
1 year
+82.66%
Open
21.53
Prev close
21.51
Mkt cap
7.12B
Vol
5.02M
Avg vol
2.84M
EPS
0.49
P/E
41.71
Div yield
0.00%
More statistics
Low
20.30
High
21.68
Forward P/E
16.94
Beta
1.21
Short ratio
3.80
Inst. own
48.57%
Dividend
0.00
Ex-div date
Earnings
Nov 3, 2026
50-d avg
19.12
200-d avg
15.74
1y target
23.43

3M chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Aug 3, 2026Rating: UBS · Buy → Buy
  • Sep 9, 2026Rating: Leerink Partners · — → Outperform
  • Sep 17, 2026Rating: Barclays · Overweight → Overweight
  • Sep 23, 2026Rating: Oppenheimer · — → Outperform
  • Oct 22, 2026Rating: JP Morgan · Overweight → Overweight
Signals (14)
NameDateAgo
MACD: Buy SignalOct 23, 20261 week ago
SMA: BullishOct 15, 20262 weeks ago
SMA: BearishOct 14, 20262 weeks ago
MACD: Sell SignalOct 8, 20263 weeks ago
RSI: OverboughtSep 21, 20261 month ago
MACD: Buy SignalSep 17, 20261 month ago
SMA: BullishSep 16, 20261 month ago
SMA: BullishSep 16, 20261 month ago
SMA: BearishSep 4, 20261 month ago
SMA: BullishSep 2, 20262 months ago
SMA: BearishAug 28, 20262 months ago
SMA: BearishAug 20, 20262 months ago
SMA: BullishAug 14, 20262 months ago
SMA: BearishAug 11, 20262 months ago

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 23.43 +14.6% upside
Target (low)
20.00
Target (mean)
23.43
Target (high)
27.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
  • Strong buy3
  • Buy4
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 7
  • 1 month ago 7
  • 2 months ago 5

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

AMRX analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter0.23740.202 – 0.280.17+39.7%817.86M+4.3%7
Next quarter0.222760.18 – 0.240.21+6.1%825.18M+1.3%7
Current year1.030.978 – 1.050.83+24.1%3.16B+4.7%7
Next year1.211.08 – 1.311.03+17.1%3.46B+9.4%7

Upgrades and downgrades

The latest rating changes

AMRX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 22, 2026JP MorganMaintainedOverweightOverweight
Sep 23, 2026OppenheimerInitiated—Outperform
Sep 17, 2026BarclaysMaintainedOverweightOverweight
Sep 9, 2026Leerink PartnersInitiated—Outperform
Aug 3, 2026UBSMaintainedBuyBuy
Jul 15, 2026UBSMaintainedBuyBuy
May 20, 2026BarclaysMaintainedOverweightOverweight
Apr 17, 2026UBSInitiated—Buy
Mar 2, 2026Truist SecuritiesMaintainedBuyBuy
Dec 9, 2025BarclaysInitiated—Overweight
Oct 31, 2025Piper SandlerReiteratedOverweightOverweight
Sep 16, 2025JP MorganMaintainedOverweightOverweight
Mar 3, 2025BarclaysMaintainedOverweightOverweight
Feb 24, 2025JP MorganUpgradeNeutralOverweight
Nov 11, 2024Piper SandlerMaintainedOverweightOverweight
Oct 2, 2024Truist SecuritiesMaintainedBuyBuy
Sep 6, 2024JP MorganUpgradeUnderweightNeutral
Aug 13, 2024BarclaysMaintainedOverweightOverweight
Aug 12, 2024Truist SecuritiesMaintainedBuyBuy
May 6, 2024Goldman SachsMaintainedBuyBuy
May 6, 2024Truist SecuritiesReiteratedBuyBuy
Mar 21, 2024Piper SandlerMaintainedOverweightOverweight
Mar 4, 2024Goldman SachsMaintainedBuyBuy
Jan 29, 2024BarclaysMaintainedOverweightOverweight
Nov 8, 2023Truist SecuritiesMaintainedBuyBuy
Sep 6, 2023Truist SecuritiesReiteratedBuyBuy
Aug 7, 2023Piper SandlerMaintainedOverweightOverweight
Aug 7, 2023Truist SecuritiesMaintainedBuyBuy
Aug 7, 2023BarclaysMaintainedOverweightOverweight
May 8, 2023Piper SandlerMaintained—Overweight